

Status: Currently Official on 13-Feb-2025  
Official Date: Official as of 01-May-2017  
Document Type: USP Monographs  
DocId: GUID-7272D21D-DA2F-45A9-9143-4CFE36FDDA70\_2\_en-US  
DOI: [https://doi.org/10.31003/USPNF\\_M265\\_02\\_01](https://doi.org/10.31003/USPNF_M265_02_01)  
DOI Ref: 823ks

© 2025 USPC  
Do not distribute

# Acetaminophen and Codeine Phosphate Oral Suspension

## DEFINITION

Acetaminophen and Codeine Phosphate Oral Suspension is a suspension of Acetaminophen and Codeine Phosphate in a suitable aqueous vehicle. It contains NLT 90.0% and NMT 110.0% of the labeled amount of acetaminophen ( $C_8H_9NO_2$ ) and codeine phosphate hemihydrate ( $C_{18}H_{21}NO_3 \cdot H_3PO_4 \cdot \frac{1}{2}H_2O$ ).

## IDENTIFICATION

• **A.** The retention times of the major peaks of the *Sample solution* correspond to those of the *Standard solution*, as obtained in the Assay.

• **B. THIN-LAYER CHROMATOGRAPHY**

**Standard solution:** 12 mg/mL each of [USP Acetaminophen RS](#) and [USP Codeine Phosphate RS](#) in methanol

**Sample solution:** Transfer a volume of Oral Suspension, equivalent to 12 mg of codeine phosphate, to a separator. Add 1 mL of ammonium hydroxide and 5 mL of methylene chloride, shake for 1 min, and allow the layers to separate. Use the clear lower layer.

**Chromatographic system**

(See [Chromatography \(621\)](#), [Thin-Layer Chromatography](#).)

**Adsorbent:** 0.25-mm layer of chromatographic silica gel mixture

**Developing solvent system:** Methanol and ammonium hydroxide (49:1)

**Application volume:** 10  $\mu$ L

**Analysis**

**Samples:** *Standard solution* and *Sample solution*

Develop the chromatogram in the *Developing solvent system* until the solvent front has moved three-fourths of the length of the plate.

Locate the spots on the plate by examination under short-wavelength UV light.

**Acceptance criteria:** The  $R_f$  values of the two principal spots of the *Sample solution* correspond to those of the *Standard solution*.

## ASSAY

• **PROCEDURE**

**Diluent:** Methanol and 0.01 N sodium hydroxide (30:70)

**Mobile phase:** Dissolve 4.9 g of monobasic potassium phosphate in 900 mL of water, adjust with phosphoric acid to a pH of 3.9, and add 216 mg of sodium 1-octanesulfonate. Add 100 mL of acetonitrile, and filter.

**Codeine phosphate standard stock solution:** 0.5 mg/mL of [USP Codeine Phosphate RS](#) in *Diluent*

**Standard stock solution:** Transfer a quantity of 5J mg of [USP Acetaminophen RS](#) (J being the ratio of the labeled amount, in mg, of acetaminophen to the labeled amount, in mg, of codeine phosphate hemihydrate) and 10.0 mL of *Codeine phosphate standard stock solution* to a 100-mL volumetric flask. Dissolve in and dilute with *Diluent* to volume.

**System suitability stock solution:** 0.02 mg/mL of sodium benzoate and 0.03 mg/mL of methylparaben in *Diluent*

**System suitability solution:** Transfer 10.0 mL of the *System suitability stock solution* to a 50-mL volumetric flask, add 10.0 mL of *Standard stock solution*, and dilute with *Mobile phase* to volume.

**Standard solution:** 0.01 mg/mL of [USP Codeine Phosphate RS](#) and 0.01J mg/mL of [USP Acetaminophen RS](#) in *Mobile phase*. Prepare by diluting 10.0 mL of the *Standard stock solution* with *Mobile phase* to 50 mL in a volumetric flask.

**Sample stock solution:** Nominally 0.5 mg/mL of acetaminophen and 0.5 mg/mL of codeine phosphate hemihydrate in *Diluent* prepared as follows. Transfer a measured volume of well-mixed Oral Suspension, equivalent to 50 mg of acetaminophen, to a 100-mL volumetric flask. Add 50 mL of *Diluent*, and mix by mechanical means for 30 min. Dilute with *Diluent* to volume. Foaming may be minimized by adding a few drops of acetonitrile before diluting with *Diluent* to volume. Centrifuge a portion of this mixture.

**Sample solution:** Dilute 10.0 mL of the clear supernatant from the *Sample stock solution* with *Mobile phase* to 50 mL in a volumetric flask.

**Chromatographic system**

(See [Chromatography \(621\)](#), [System Suitability](#).)

**Mode:** LC

**Detector:** UV 220 nm

**Column:** 4.6-mm  $\times$  15-cm; 5- $\mu$ m packing L11

**Flow rate:** 2 mL/min

**Injection volume:** 20  $\mu$ L

**System suitability**

**Samples:** *System suitability solution* and *Standard solution*

[NOTE—The relative retention times for acetaminophen, benzoate, codeine, and methylparaben are about 0.25, 0.5, 1.0, and 1.3, respectively.]

#### Suitability requirements

**Resolution:** NLT 2 between each pair of adjacent peaks, *System suitability solution*

**Tailing factor:** NMT 2 for each analyte peak, *Standard solution*

**Relative standard deviation:** NMT 2.0%, *Standard solution*

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of acetaminophen ( $C_8H_9NO_2$ ) in the portion of Oral Suspension taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

$r_U$  = peak response of acetaminophen from the *Sample solution*

$r_S$  = peak response of acetaminophen from the *Standard solution*

$C_S$  = concentration of [USP Acetaminophen RS](#) in the *Standard solution* (mg/mL)

$C_U$  = nominal concentration of acetaminophen in the *Sample solution* (mg/mL)

**Acceptance criteria:** 90.0%–110.0%

Calculate the percentage of the labeled amount of codeine phosphate hemihydrate ( $C_{18}H_{21}NO_3 \cdot H_3PO_4 \cdot \frac{1}{2}H_2O$ ) in the portion of Oral Suspension taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$$

$r_U$  = peak response of codeine from the *Sample solution*

$r_S$  = peak response of codeine from the *Standard solution*

$C_S$  = concentration of [USP Codeine Phosphate RS](#) in the *Standard solution* (mg/mL)

$C_U$  = nominal concentration of codeine phosphate hemihydrate in the *Sample solution* (mg/mL)

$M_{r1}$  = molecular weight of codeine phosphate hemihydrate, 406.37

$M_{r2}$  = molecular weight of anhydrous codeine phosphate, 397.37

**Acceptance criteria:** 90.0%–110.0%

#### PERFORMANCE TESTS

- [UNIFORMITY OF DOSAGE UNITS \(905\)](#).

##### For single-unit containers

**Acceptance criteria:** Meets the requirements

- [DELIVERABLE VOLUME \(698\)](#).

##### For multiple-unit containers

**Acceptance criteria:** Meets the requirements

#### IMPURITIES

- [4-AMINOPHENOL IN ACETAMINOPHEN-CONTAINING DRUG PRODUCTS \(227\)](#): Meets the requirements

#### SPECIFIC TESTS

- [pH \(791\)](#): 4.0–6.1

#### ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in tight, light-resistant containers, and store at controlled room temperature.
- [USP REFERENCE STANDARDS \(11\)](#).  
[USP Acetaminophen RS](#)  
[USP Codeine Phosphate RS](#)

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
ACETAMINOPHEN AND CODEINE PHOSPHATE ORAL SUSPENSION	<a href="#">Documentary Standards Support</a>	SM22020 Small Molecules 2

Chromatographic Database Information: [Chromatographic Database](#)

---

**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. PF 41(6)

**Current DocID:** GUID-7272D21D-DA2F-45A9-9143-4CFE36FDDA70\_2\_en-US

**Previous DocID:** GUID-7272D21D-DA2F-45A9-9143-4CFE36FDDA70\_1\_en-US

**DOI:** [https://doi.org/10.31003/USPNF\\_M265\\_02\\_01](https://doi.org/10.31003/USPNF_M265_02_01)

**DOI ref:** [823ks](#)

OFFICIAL